INmune
Bio (NASDAQ: INMB) on Monday announced that Malú Tansey, Ph.D.,
Professor of Neuroscience and Director of the Center for Translational Research
in Neurodegenerative Disease at the University of Florida College of Medicine,
presented data that demonstrated the use of INmune Bio’s lead compound,
XPro1595, to lessen the exacerbation of Alzheimer’s-like pathology brought on
by a high fat and high fructose diet in mice. Dr. Tansey presented the data as
the lead speaker at a press conference during the Society for Neuroscience 49th
Annual Meeting in Chicago. “The new data strengthen our findings that a
potential connection between diets rich in fat and sugar and chronic
inflammation can lead to an increased risk for Alzheimer’s disease,” Dr. Malú
Tansey stated in the news release. “With more than 93 million obese people in
the U.S., according to the most recent data from the Centers for Disease
Control and Prevention, understanding the link between obesity and Alzheimer’s
disease is more relevant now than ever. By targeting inflammation with XPro1595
we may be able to effectively treat neurodegenerative diseases.”
To view the full press release, visit http://ibn.fm/DCqzc
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded, clinical-stage
biotechnology company developing therapies targeting the innate immune system
to fight disease. INmune Bio is developing three product platforms: two
products that reengineer the patient’s innate immune system’s response to
cancer and one product to treat neuroinflammation that is currently focused on
Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that
primes the patient’s NK cells to attack minimal residual disease, the remaining
cancer cells that are difficult to detect, which often cause relapse. INB03
inhibits myeloid-derived suppressor cells (“MDSC”), which often cause
resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595
targets neuroinflammation, which causes microglial activation and neuronal cell
death. INmune Bio’s product platforms utilize a precision medicine approach for
the treatment of a wide variety of hematologic malignancies, solid tumors and
chronic inflammation. For more information, visit the company’s website
at www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
